Pfizer’s lorlatinib clears first hurdle to UK early access scheme
Pfizer’s lorlatinib has been designated a Promising Innovative Medicine for the treatment of some patients with ALK-positive advanced non-small cell lung cancer.
Read More
Tag: PIM
PIM status for Boehringer’s mesothelioma drug
Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.
Read More
Akcea’s rare lipid disorder drug wins PIM status
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder.
Read More
Merck, Pfizer’s avelumab clears first hurdle in early access scheme
Patients with Merkel Cell Carcinoma living in the UK are a step closer to getting early access to Merck and Pfizer’s avelumab after regulators assigned the drug Promising Innovative Medicines (PIM) status.
Read More
Roche’s Tecentriq joins UK’s early access to meds scheme
Roche’s Tecentriq has been accepted onto the UK’s Early Access to Medicines Scheme (EAMS), having picked up a positive scientific opinion from the Medicines and Healthcare products Regulatory Agency for the treatment of bladder cancer.
Read More
Vtesse’s Niemann-Pick C therapy awarded PIM status
An investigational therapy in development for the treatment of Niemann-Pick Type C1 disease (NPC) has been awarded Promising Innovative Medicine (PIM) status by the Medicines and Healthcare products Regulatory Agency.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
